TO

TORII PHARMACEUTICAL CO., LTD.

A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.

4551 | T

Overview

Corporate Details

ISIN(s):
JP3635800000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目4番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Torii Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and marketing of ethical drugs. The company focuses its business activities on key therapeutic areas, including renal diseases and hemodialysis, skin diseases, and allergies. Its product portfolio addresses conditions such as atopic dermatitis and pruritus associated with chronic kidney disease. Following a tender offer completed in 2025, the company operates as a subsidiary of Shionogi & Co., Ltd.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-07 06:04
Regulatory News Service
確認書
Japanese 9.3 KB
2025-08-07 06:01
Interim Report
半期報告書-第134期(2025/01/01-2025/12/31)
Japanese 215.6 KB
2025-07-10 08:30
Share Issue/Capital Change
臨時報告書
Japanese 215.5 KB
2025-06-19 02:04
Major Shareholding Notification
臨時報告書
Japanese 23.2 KB
2025-06-04 09:05
M&A Activity
訂正意見表明報告書
Japanese 171.8 KB
2025-05-08 08:56
Regulatory News Service
意見表明報告書
Japanese 373.9 KB
2025-03-31 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 24.8 KB
2025-03-27 07:23
Governance Information
内部統制報告書-第133期(2024/01/01-2024/12/31)
Japanese 24.0 KB
2025-03-27 07:22
Registration Form
確認書
Japanese 9.3 KB
2025-03-27 07:18
Annual Report
有価証券報告書-第133期(2024/01/01-2024/12/31)
Japanese 1.0 MB
2024-08-01 03:06
Interim Report
確認書
Japanese 9.2 KB
2024-08-01 03:05
Interim Report
半期報告書-第133期(2024/01/01-2024/12/31)
Japanese 187.0 KB
2024-04-26 08:07
Report Publication Announcement
確認書
Japanese 9.2 KB
2024-04-26 08:06
Quarterly Report
四半期報告書-第133期第1四半期(2024/01/01-2024/03/31)
Japanese 143.5 KB
2024-03-29 07:17
Post-Annual General Meeting Information
臨時報告書
Japanese 39.3 KB

Automate Your Workflow. Get a real-time feed of all TORII PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TORII PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TORII PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America ALLO
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America ALNY

Talk to a Data Expert

Have a question? We'll get back to you promptly.